Top

BMC Urology

Published in:

Open Access 01-12-2015 | Research article

Vapoenucleation of the prostate using a high-power thulium laser: a one-year follow-up study

Authors: Ching-Hsin Chang, Tzu-Ping Lin, Yen-Hwa Chang, William JS Huang, Alex TL Lin, Kuang-Kuo Chen

Published in: BMC Urology | Issue 1/2015

Abstract

Background

Prostate vaporization and enucleation is a novel treatment option for bladder outlet obstruction caused by benign prostate enlargement. This surgical technique, however, has not yet been standardized. We present our findings of using a high-power thulium laser to accomplish vapoenucleation of the prostate (ThuVEP).

Methods

We prospectively collected and analyzed data from 29 patients who underwent ThuVEP between August 2010 and May 2012. The control group included 30 patients who underwent traditional transurethral resection of the prostate (TURP). Operative variables, patient profiles, preoperative and postoperative urine flow rates, prostate volume (measured using transrectal ultrasonography), and the international prostate symptom score (IPSS) were recorded and analyzed using a two-tailed Student’s t-test and analysis of variance.

Results

The ages (mean ± SD) of the patients were 76.1 ± 9.4 and 72.6 ± 7.4 years (p = 0.28) in the ThuVEP and TURP groups, respectively. The average urinary flow rates before and 12 months after the operation (volume/maximum flow/average flow) were 243.3/10.5/5.0 and 302.8/17.6/9.4 (in mL, mL/s, mL/s, respectively) in the ThuVEP group and 247.2/10.8/4.6 and 369.9/20.8/12.0, respectively, in the TURP group. Preoperative and postoperative IPSSs were 17.1 ± 5.0 and 6.5 ± 3.8, respectively, in the ThuVEP group and 18.2 ± 4.5 and 6.2 ± 3.3, respectively, in the TURP group. The mean ratio of the estimated postoperative residual prostate volume to the preoperative total volume was 0.47 (p = 0.449) in both groups. The overall complication rate was 20.7% in the ThuVEP group and 30.0% in the TURP group.

Conclusions

One year of follow-up showed that ThuVEP and TURP effectively alleviated subjective and objective voiding symptoms with a low rate of complications. Thus, vapoenucleation using a high-power laser is feasible in elderly patients.

Trial registration

ISRCTN registry with study ID ISRCTN52339705. Date assigned: 06/03/2015.

Lo KL, Chan MC, Wong A, Hou SM, Ng CF. Long-term outcome of patients with a successful trial without catheter, after treatment with an alpha-adrenergic receptor blocker for acute urinary retention caused by benign prostatic hyperplasia. Int Urol Nephrol. 2010;42:7–12.CrossRefPubMed

Merrill RM, Hunter BD. The diminishing role of transurethral resection of the prostate. Ann Surg Oncol. 2010;17:1422–8.CrossRefPubMed

Robert G, Descazeaud A, de la Taille A. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: who are the high-risk patients and what are the best treatment options? Curr Opin Urol. 2011;21:42–8.CrossRefPubMed

Flanigan RC, Reda DJ, Wasson JH, Anderson RJ, Abdellatif M, Bruskewitz RC. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a department of veterans affairs cooperative study. J Urol. 1998;160:12–6. discussion 6–7.CrossRefPubMed

Hoekstra RJ, Van Melick HH, Kok ET, Ruud Bosch JL. A 10-year follow-up after transurethral resection of the prostate, contact laser prostatectomy and electrovaporization in men with benign prostatic hyperplasia; long-term results of a randomized controlled trial. BJU Int. 2010;106:822–6.CrossRefPubMed

Masumori N, Furuya R, Tanaka Y, Furuya S, Ogura H, Tsukamoto T. The 12-year symptomatic outcome of transurethral resection of the prostate for patients with lower urinary tract symptoms suggestive of benign prostatic obstruction compared to the urodynamic findings before surgery. BJU Int. 2010;105:1429–33.CrossRefPubMed

Jeldres C, Isbarn H, Capitanio U, Zini L, Bhojani N, Shariat SF, et al. Development and external validation of a highly accurate nomogram for the prediction of perioperative mortality after transurethral resection of the prostate for benign prostatic hyperplasia. J Urol. 2009;182:626–32.CrossRefPubMed

Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol. 2008;180:246–9.CrossRefPubMed

Gilling PJ, Mackey M, Cresswell M, Kennett K, Kabalin JN, Fraundorfer MR. Holmium laser versus transurethral resection of the prostate: a randomized prospective trial with 1-year followup. J Urol. 1999;162:1640–4.CrossRefPubMed

10.

Krambeck AE, Handa SE, Lingeman JE. Experience with more than 1,000 holmium laser prostate enucleations for benign prostatic hyperplasia. J Urol. 2010;183:1105–9.CrossRefPubMed

11.

Kuntz RM, Lehrich K, Ahyai SA. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol. 2008;53:160–6.CrossRefPubMed

12.

Gnessin E, Mandeville JA, Lingeman JE. An update on holmium laser enucleation of the prostate and why it has stood the test of time. Curr Opin Urol. 2011;21:31–5.CrossRefPubMed

13.

Placer J, Gelabert-Mas A, Vallmanya F, Manresa JM, Menéndez V, Cortadellas R, et al. Holmium laser enucleation of prostate: outcome and complications of self-taught learning curve. Urology. 2009;73:1042–8.CrossRefPubMed

14.

Fried NM, Murray KE. High-power thulium fiber laser ablation of urinary tissues at 1.94 microm. J Endourol. 2005;19:25–31.CrossRefPubMed

15.

Fried NM. High-power laser vaporization of the canine prostate using a 110 w thulium fiber laser at 1.91 microm. Lasers Surg Med. 2005;36:52–6.CrossRefPubMed

16.

Bach T, Herrmann TR, Ganzer R, Burchardt M, Gross AJ. RevoLix vaporesection of the prostate: initial results of 54 patients with a 1-year follow-up. World J Urol. 2007;25:257–62.CrossRefPubMed

17.

Shao Q, Zhang FB, Shang DH, Tian Y. Comparison of holmium and thulium laser in transurethral enucleation of the prostate]. Zhonghua Nan Ke Xue. 2009;15:346–9.PubMed

18.

Xia SJ, Zhang YN, Lu J, Sun XW, Zhang J, Zhu YY, et al. Thulium laser resection of prostate-tangerine technique in treatment of benign prostate hyperplasia. Zhonghua Yi Xue Za Zhi. 2005;85:3225–8.PubMed

19.

Xia SJ, Zhuo J, Sun XW, Han BM, Shao Y, Zhang YN. Thulium laser versus standard transurethral resection of the prostate: a randomized prospective trial. Eur Urol. 2008;53:382–9.CrossRefPubMed

20.

Oesterling JE, Kumamoto Y, Tsukamoto T, Girman CJ, Guess HA, Masumori N, et al. Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Br J Urol. 1995;75:347–53.CrossRefPubMed

21.

Gilling P. Holmium laser enucleation of the prostate (HoLEP). BJU Int. 2008;101:131–42.CrossRefPubMed

22.

Vroege JA. The sexual health inventory for men (IIEF-5). Int J Impot Res. 1999;11:177.CrossRefPubMed

23.

Smith RD, Patel A. Transurethral resection of the prostate revisited and updated. Curr Opin Urol. 2011;21:36–41.CrossRefPubMed

24.

Bach T, Xia SJ, Yang Y, Mattioli S, Watson GM, Gross AJ, et al. Thulium: YAG 2 mum cw laser prostatectomy: where do we stand? World J Urol. 2010;28:163–8.CrossRefPubMed

25.

Herrmann TR, Bach T, Imkamp F, Georgiou A, Burchardt M, Oelke M, et al. Thulium laser enucleation of the prostate (ThuLEP): transurethral anatomical prostatectomy with laser support. Introduction of a novel technique for the treatment of benign prostatic obstruction. World J Urol. 2010;28:45–51.CrossRefPubMed

26.

Bach T, Wendt-Nordahl G, Michel MS, Herrmann TR, Gross AJ. Feasibility and efficacy of Thulium:YAG laser enucleation (VapoEnucleation) of the prostate. World J Urol. 2009;27:541–5.CrossRefPubMed

27.

Morgan M, Smith N, Thomas K, Murphy DG. Is Clavien the new standard for reporting urological complications? BJU Int. 2009;104:434–6.CrossRefPubMed

28.

Descazeaud A, Robert G, Lebdai S, Bougault A, Azzousi AR, Haillot O, et al. Impact of oral anticoagulation on morbidity of transurethral resection of the prostate. World J Urol. 2011;29:211–6.CrossRefPubMed

Title: Vapoenucleation of the prostate using a high-power thulium laser: a one-year follow-up study
Authors: Ching-Hsin Chang
Tzu-Ping Lin
Yen-Hwa Chang
William JS Huang
Alex TL Lin
Kuang-Kuo Chen
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: BMC Urology / Issue 1/2015
Electronic ISSN: 1471-2490
DOI: https://doi.org/10.1186/s12894-015-0032-7

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Vapoenucleation of the prostate using a high-power thulium laser: a one-year follow-up study

Abstract

Background

Methods

Results

Conclusions

Trial registration

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2015

Localization of P2X receptor subtypes 2, 3 and 7 in human urinary bladder

The role of diagnostic ureteroscopy in the era of computed tomography urography

Heavy hematuria requiring cystectomy in a patient with hemophilia A: a case report and literature review

Association between plasma fluorescent oxidation products and erectile dysfunction: A prospective study

Diagnostic outcome of ureteroscopy in urothelial carcinoma of the upper urinary tract: Incidence of later cancer detection and its risk factors after the first examination

Urethral orifice hyaluronic acid injections: a novel animal model of bladder outlet obstruction